The TNFR2M196R germline variant confers dual impact on CAR-T cell immunotherapy by enhancing T-cell survival and tumor proliferation
{{output}}
Despite its remarkable efficacy in hematologic malignancies, chimeric antigen receptor T-cell (CAR-T) therapy is often limited by atypical clinical outcomes, necessitating predictive biomarkers. Here, prompted by a patient with low-tumor-burden non-Hodgkin lym... ...
